Different Strokes for Different Folks
effects of different Covid brands on bleeding and clotting

By Craig Paardekooper

Data source :Spreadsheet for this study : spreadsheet
European Safety Signal Dataset (E.S.S.D) : data
Background to E.S.S.D : background

Summary of Findings
1. Vaxzevria is associated with a significantly higher incidence of thrombosis compared to other brands of Covid jab
2. Comirnaty is associated with significantly higher incidence of menstrual bleeding, menorrhagia, uterine and breast disorders compared to other brands ofCovid jab

If Vaxzevria is the “Clot Shot” – effecting veins and arteries throughout the bodythen Comirnaty is the “Crotch Shot” – since it targets the reproductive system, causing excessive bleeding and ovulatory disorderIntroduction
This study was born out of a curiosity – a peculiar pattern in the symptoms for the Covid jab “Comirnaty” which indicated a strong focus of the “vaccine’s “ effects
upon the reproductive organs.
It was natural for me to look at other brands of Covid jab, to see if the same patterns persisted there. I was surprised to find that other brands each seemed focusedin different ways, as if testing the effects on different organ systems and different degrees of distribution.
So, it all began with an investigation of the effects of these jabs on the menstrual – ovulatory cycle.

Previous Studies of Menstrual Disorder
Dr John Campbell had published a video on menstrual irregularities following the COVID jab. See here. In this video, Dr Campbell discussed two studies In the first study, out of 78,138 vaccinated women, 39,759 (52.05%) had some form of menstrual problem after COVID vaccination.
In the second study, the Norwegian Institute of Public Health followed several cohorts throughout the pandemic and early performed a systematic data collection ofself-reported unexpected vaginal bleeding in non-menstruating women. This study found –Among 7725 post-menopausal women, 7148 peri-menopausal women, and 7052 pre-menopausal women, 3.3, 14.1, and 13.1% experienced unexpectedvaginal bleeding during a period of 8 to 9 months, respectively. In post-menopausal women, the risk of unexpected vaginal bleeding (i.e., post-menopausalbleeding) in the 4 weeks after COVID-19 vaccination was increased two- to threefold, compared to a pre-vaccination period. The corresponding risk ofunexpected vaginal bleeding after vaccination was increased three- to fivefold in both non-menstruating peri- and pre-menopausal women. In the premenopausal women, Spikevax was associated with at 32% increased risk as compared to Comirnaty.

First Indications of A Significant Distribution
Using proportional reporting ratio, I had previously found that COVID jabs consistently generate safety signals for these disorders – see here and here.
However, I did not know how these menstrual symptoms ranked relative to all the other symptoms - I assumed that menstrual symptoms were just one amongst
many, and that all Covid jab brands would have about the same incidence. I proceeded to look at all the symptoms associated with Covid jabs, and rank each symptom
in order of proportional reporting ratio.
The first surprise was the high incidence of several forms of menstrual disorder with the Covid jab – Comirnaty.

Fig 1 : PRR scores for symptoms associated with COMIRNATY.
Here are the top 32 symptoms in order of PRR. Nothing has been added or taken away. This is exactly
how the output looks when simply ordered by PRR.
You can see that a large number of these symptoms are related to menstrual disorder (shaded inblue). This was unexpected. Disorders of the menstrual-ovulatory cycle now appeared as the leadingclass of symptoms for Comirnaty.

Fig 2 : PRR scores for symptoms associated with MODERNA
Naturally, I wanted to see if other brands of Covid jab also had the same high incidence of menstrual
disorder. As you can see, for Moderna a few symptoms of menstrual disorder still appear in the top 32
symptoms (shaded in blue), but this is far less than the incidence with Comirnaty.
What appears to predominate instead are a high incidence of vaccination site symptoms (shaded inyellow).
This suggested to me that the Moderna jab is more localized to the injection site – that it does not biodistribute to the same extent as the Comirnaty jab.
There is absolutely no way that all these vaccination site symptoms would just appear with top ranks
together unless this was a very powerful characteristic of the Moderna jab. It must have been designed
to stay at the injection site.
Though when it did bio-distribute, it seems to have mainly effected the reproductive organs –• Menoletrorrhagia• Pre-mentrual syndrome• Adnexa uteri pain
• Cervicobrachial syndrome• Odynophagia• Uterine pain
• Oligomenorrhoea• Mechanical Urticaria
This list seems to be very focused on the reproductive organs.
I would suggest that both Comirnaty and Moderna target the reproductive organs, but that Modena wasdesigned to stay more at the injection site, whilst Comirnaty was not.
It is quite incredible that all of the symptoms that are not vaccination site symptoms, are almost allsymptoms relating to the reproductive organs.

The takeaway here is that there are significant differences between the symptom profiles for different
Covid jabs.

Fig 3 : PRR scores for symptoms associated with VAXZEVRIAIn the top 32 symptoms, menstrual disorders were completely absent, and there was only one single
vaccination site symptom ! Instead there were several symptoms relating to thrombosis, embolism andheadache.
Severe or sharp headaches are a symptom of blood clot in the brain, so these symptoms may be related.

“Symptoms of cavernous sinus thrombosis include: a sharp and severe headache, particularly aroundthe eye. swelling and bulging of the eye(s) and the surrounding tissues.”
See https://www.nhs.uk/conditions/cavernous-sinus-thrombosis/

Note that sinus headache and sinus thrombosis both occur in this list, as well as retinal migraine – so it iscertain that VAXZEVRIA was generating blood clots in the brain. In fact the leading symptom for VAXZEVRIA
is thrombosis with thrombocytopenia – and this jab was generally referred to as the “clot shot”.

Once again, this brand of Covid jab had a distinct profile of symptoms – different from the profiles forModerna or for Comirnaty.

So, in this study I take a closer look at these differences – focusing on thrombosis and on menstrual
disorder.

MethodThe following tables show the Proportional Reporting Ratios (PRR) for each symptom with each Covid jab. Aboxplot is generated showing the spread of these PRR scores. Significant differences in spread are noted.

TARGETTING THE VASCULAR SYSTEM – THROMBOSISTARGETTING MENSTRUAL CYCLETARGETTING OVULATIONTARGETTING THE UTERUSTARGETTING THE BREASTS